If you've just had lipoprotein(a) — Lp(a) — measured for the first time, the result can be confusing. It might be reported in nmol/L or in mg/dL, and there's no single universal cut-off for "high." This guide gives you the short answer, then explains what the number means and why the units matter.
What counts as a high Lp(a)?
A high Lp(a) is generally considered above ~125 nmol/L (roughly ~50 mg/dL). Below ~75 nmol/L (~30 mg/dL) is usually considered low risk; ~75–125 nmol/L is an intermediate "grey zone"; above ~250 nmol/L (~100 mg/dL) is very high. These are reference points, not diagnostic cut-offs — roughly 1 in 5 adults falls in the elevated range, and your physician interprets your result alongside your full risk picture.
Lp(a) Reference Ranges at a Glance
Lp(a) is best reported in nmol/L (which counts particles). Where a result is given in mg/dL, the approximate equivalents are shown alongside — but see the units section below, because the two do not convert by a single fixed factor.
Lp(a) Risk Bands (nmol/L)
| Category | Lp(a) — nmol/L (primary) | Approx. mg/dL |
|---|---|---|
| Low risk | below ~75 | below ~30 |
| Grey zone | ~75–125 | ~30–50 |
| High | above ~125 | above ~50 |
| Very high | above ~250 | above ~100 |
Reference points only — exact thresholds vary by guideline, laboratory, and assay, and interpretation belongs to your physician. Track your result in nmol/L and compare like with like over time.
Two Units — and Why They Don't Convert Cleanly
Lp(a) can be reported two ways, and this is the single most common source of confusion:
- nmol/L (nanomoles per litre) counts the number of Lp(a) particles. This is the preferred, more accurate unit.
- mg/dL (milligrams per decilitre) measures the mass of the particles.
You'll often see "divide by ~2.15" or "multiply by ~2.4" rules to convert between them. Treat these as rough approximations only. Because Lp(a) particles vary in size from person to person, there is no single accurate conversion factor — the true relationship depends on the individual and the laboratory assay used.
Practical rule: track your Lp(a) in nmol/L where possible, and when comparing an old result to a new one, make sure both are in the same unit before drawing any conclusion. A "change" that's really just a unit difference is a common false alarm.
"Normal" vs. "Optimal": Reading Your Result
As with ApoB, there's an important difference between a laboratory's reference range and a risk-based threshold. A lab range describes what's statistically common in the population; a risk threshold describes the level above which cardiovascular risk begins to climb. For Lp(a), the useful question isn't "am I inside the lab range?" but "where do I sit relative to the level that starts to matter for my heart?"
This is why a result can be labelled unremarkable on a report and still be worth acting on — not by lowering Lp(a) directly, but by tightening every other risk factor. For the full picture of how Lp(a) differs from a standard cholesterol reading, see Lp(a) vs LDL.
Higher means higher risk
Lp(a) rises with risk in a continuous way — there's no level below which it's suddenly "safe," and no upper level that's suddenly hopeless.
Units matter
nmol/L and mg/dL don't convert cleanly. Compare like with like, and prefer nmol/L.
Common
Roughly 1 in 5 adults sits in the elevated range — yet most have never had Lp(a) measured.
Usually tested once
Because Lp(a) is genetic and stable for life, a single accurate measurement is generally enough.
What a High Result Does — and Doesn't — Mean
A high Lp(a) means you carry an inherited factor that raises your lifetime risk of heart attack, stroke, and aortic valve narrowing. It does not mean any of those things are inevitable, and it is not a diagnosis of disease.
It's also worth being clear about what a high number changes in practice. There is currently no approved medication that lowers Lp(a), and diet or exercise won't move it meaningfully — so a high result doesn't come with an "Lp(a) pill." What it does is raise the stakes on everything else: it's a strong reason to drive your ApoB and LDL-C to target, control blood pressure, and consider testing family members. The pillar guide walks through this in full — see Lp(a): The Complete Guide.
Common Questions
As a rough guide, above ~50 mg/dL is generally considered high and above ~30 mg/dL enters an intermediate range — but mg/dL and nmol/L don't convert by a fixed factor, so these are approximations. If you can, ask your lab to report Lp(a) in nmol/L for a more reliable read.
There's no single normal number in the way there is for, say, glucose. Lp(a) risk rises continuously with the level, so it's better framed as low, intermediate, high, or very high — with lower being better. Your physician interprets your value in the context of your overall risk.
First, check the units. A very common cause of an apparent change is one result being in nmol/L and the other in mg/dL. Genuine Lp(a) levels are largely stable across life, so a real, large shift is unusual and worth discussing with your doctor.
Not with current approved treatments, and not meaningfully through diet or exercise — Lp(a) is genetic. The effective strategy is to lower every other cardiovascular risk factor aggressively. Several Lp(a)-specific therapies are in trials but are not yet approved. See the pillar guide for the full picture.
See Where Your Lp(a) Stands
CardioIQ interprets your Lp(a) alongside your ApoB, lipids, and full risk profile — against longevity-optimal targets, not just population ranges — in a structured, physician-grade report.
Important Medical Notice. This article is for education only. It is not medical advice, not a diagnosis, and not a substitute for care from a qualified clinician. Reference ranges and units vary by laboratory and assay. CardioIQ interprets biomarker data; it does not diagnose or treat disease and does not replace your treating physician. Always discuss your results and any decisions with your physician.
References
- Kronenberg F, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal, 2022.
- 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal. doi:10.1093/eurheartj/ehz455